JPP 2008, 60: 1375–1383
ß 2008 The Authors
Received March 31, 2008
Accepted June 11, 2008
DOI 10.1211/jpp/60.10.0014
ISSN 0022-3573
Department of Biological and
Biomedical Sciences, Aga Khan
University, Karachi, Pakistan
Muhammad N. Ghayur,
Anwarul H. Gilani, Touqeer
Ahmed
Pharmacognosy Research
Laboratory, Department of
Pharmacy, King’s College London,
London, UK
Muhammad N. Ghayur, Joseph
M. Agbedahunsi, Peter J.
Houghton
Medicinal and Aromatic Plants
Research Institute, National Center
for Research, Khartoum, Sudan
Asaad Khalid
Dr Panjwani Center for Molecular
Medicine and Drug Research,
University of Karachi, Karachi,
Pakistan
Asaad Khalid, Sarfraz A. Nawaz,
Muhammad I. Choudhary
Drug Research and Production
Unit, Faculty of Pharmacy,
Obafemi Awolowo University, Ile
Ife, Nigeria
Joseph M. Agbedahunsi
Correspondence:
Anwarul H. Gilani, Department
of Biological and Biomedical
Sciences, Aga Khan University,
Karachi 74800, Pakistan.
E-mail: anwar.gilani@aku.edu
Acknowledgements and
funding: The authors are
extremely grateful to Dr Charlie
Goldsmith, Professor Emeritus,
Department of Clinical
Epidemiology and Biostatistics,
McMaster University, Hamilton,
Ontario, Canada, for his help
with the statistical analysis of
data. This study was supported
by grants made available to
Dr Anwarul H. Gilani from the
Pakistan Science Foundation and
Higher Education Commission of
Pakistan. Dr Asaad Khalid is
grateful to Sudan Academy of
Sciences (Khartoum, Sudan) for
financial support.
Muscarinic, Ca++ antagonist and specific
butyrylcholinesterase inhibitory activity of dried ginger
extract might explain its use in dementia
Muhammad N. Ghayur, Anwarul H. Gilani, Touqeer Ahmed, Asaad Khalid,
Sarfraz A. Nawaz, Joseph M. Agbedahunsi, Muhammad I. Choudhary
and Peter J. Houghton
Abstract
Ginger rhizome (Zingiber officinale) has been used for centuries to treat dementia in South Asia. This
study was undertaken to possibly justify its use. A 70% aqueous/methanolic extract of dried ginger
(Zo.Cr) was used. Zo.Cr tested positive for the presence of terpenoids, flavonoids, secondary amines,
phenols, alkaloids and saponins. When tested on isolated rat stomach fundus, Zo.Cr showed a
spasmogenic effect (0.03–5.00 mg mL-1); it relaxed the tissue at concentrations 5 mg mL-1. The
stimulant effect was resistant to blockade by hexamethonium and methysergide, but sensitive to
atropine, indicating activity via muscarinic receptors. In atropinized (0.1 mM) preparations, Zo.Cr
(0.3–3.0 mg mL-1) relaxed high K+ (80 mM)-induced contractions, indicating Ca++ antagonism in
addition to the muscarinic effect. This possible Ca++ antagonist activity was investigated in Ca++-free
conditions, with the inhibitory effect of the extract tested against contractions induced by externally
administered Ca++. Zo.Cr (0.1–0.3 mg mL-1), similar to verapamil (0.03–0.10 mM), shifted the
contractions induced by externally administered Ca++ to the right, thus suggesting an inhibitory
interaction between Zo.Cr and voltage-operated Ca++ channels. Zo.Cr (0.1–3.0 mg mL-1) also
potentiated acetylcholine peak responses in stomach fundus, similar to physostigmine, a
cholinesterase inhibitor. Zo.Cr, in an in-vitro assay, showed specific inhibition of butyrylcholinesterase
(BuChE) rather than acetylcholinesterase enzyme. Different pure compounds of ginger also showed
spasmolytic activity in stomach fundus, with 6-gingerol being the most potent. 6-Gingerol also
showed a specific anti-BuChE effect. This study shows a unique combination of muscarinic, possible
Ca++ antagonist and BuChE inhibitory activities of dried ginger, indicating its benefit in dementia,
including Alzheimer’s disease.
Introduction
Ginger rhizome (Zingiber officinale Roscoe, family Zingiberaceae) is a common food
additive, spice and a phytomedicine used since ancient times. It has long been used by
traditional healers and as a home remedy for a number of diseases (Kapoor 1990; Gilani &
Ghayur 2005). Phytochemical studies have shown that the volatile oil of ginger contains
mono- and sesquiterpenes: curcumene, geranyl acetate, terpineol, terpenes, geraniol,
-pinene, limonene, linalool, zingiberene, -besabolene and -farnesene, while the
pungent principles are gingerol, shogaol, zingerone and paradol (Langner et al 1998;
Gilani & Ghayur 2005).
There are two main forms of ginger used: fresh and dried ginger (prepared by drying the
fresh rhizome under the sun). Both varieties have their particular uses. For example, fresh
ginger is preferred to relieve colds, nausea and rid the body of toxic matter, while dried
ginger is reputed to strengthen the stomach, possessing a mild stomach and intestinal
stimulant action, and is useful in disorders of the gastrointestinal tract (especially
diarrhoea), cough and rheumatism (Foster 2000). Dried ginger has also been traditionally
used in dementia and as a memory-enhancing herb (Kapoor 1990; Duke 1995; Khan 2005).
Years of research have proven ginger’s efficacy in many disorders (Langner et al 1998;
Gilani & Ghayur 2005). Our previous work on the different forms of ginger have shown
1375
1376
Muhammad N. Ghayur et al
that dried ginger exhibits anthelmintic properties (Iqbal et al
2006), while fresh ginger possesses gastrointestinal prokinetic, laxative, antidiarrhoeal (Ghayur & Gilani 2005a, 2006;
Ghayur et al 2007), tocolytic (Ghayur & Gilani 2007),
bronchodilator, airway relaxant (Ghayur & Gilani 2007;
Ghayur et al 2008), hypotensive, vasodilator and cardiosuppressant properties (Ghayur & Gilani 2005b; Ghayur et al
2005). Continuing our endeavours to further unravel the
medicinal properties of ginger, we report here that the 70%
aqueous/methanolic extract of dried ginger exhibits muscarinic, possible Ca++ antagonist and cholinesterase inhibitory
activities. This study reiterates some of the activities that we
have already seen with the fresh ginger extract in earlier
studies, for example the gastric stimulant and relaxant
activities (Ghayur & Gilani 2005a, 2006; Ghayur et al
2007). Furthermore, this study shows for the first time that
ginger possesses cholinesterase inhibitory potential, which,
together with its muscarinic and Ca++ antagonist activities,
highlights the possible usefulness of ginger in dementia.
Drug therapy for Alzheimer’s disease (AD) has primarily
concentrated on the cholinergic system as AD progression is
accompanied by a loss of central cholinergic neurons (Muir
1997). In order to revitalize cholinergic function, approaches
have involved stimulating cholinergic receptors with muscarinic agonists or potentiating the availability of acetylcholine (ACh) by inhibiting cholinesterase enzymes (Howes &
Houghton 2003). Several muscarinic agonists have been
reported in the literature for their ability to restore
cholinergic function and attenuate cognitive function seen
in AD (Langmead et al 2008).
Materials and Methods
Drugs and standards
The following reference chemicals were obtained from
Sigma Chemical Company (St Louis, MO, USA): ACh
chloride, atropine sulfate, carbachol (CCh) chloride, hexamethonium chloride, methysergide maleate, physostigmine
hydrochloride, serotonin (5-HT) hydrochloride and verapamil hydrochloride. The following chemicals were used to
make the physiological salt solutions: potassium chloride
(Sigma Chemical Company), calcium chloride, glucose,
magnesium sulfate, potassium dihydrogen phosphate, sodium
bicarbonate and sodium chloride (E. Merck, Darmstadt,
Germany) and ethylenediaminetetra-acetic acid (EDTA)
from BDH Laboratory Supplies (Poole, England). The
commercially available ginger pure compounds namely,
6-, 8- and 10-gingerol and 6-shogaol were obtained from
Chromadex (Irvine, CA, USA). Stock solutions of all the
chemicals were made in saline and the dilutions were made
fresh on the day of the experiment.
Animals
The experiments performed complied with the rulings of the
Institute of Laboratory Animal Resources, Commission on
Life Sciences, National Research Council and were approved
by the Ethics Review Committee of Aga Khan University.
Sprague–Dawley rats (170–200 g) of either sex were housed
in the animal house of Aga Khan University under a
controlled environment (23–25˚C). They were fed a standard
diet consisting of (g kg-1): flour 380, fibre 380, molasses 12,
NaCl 5.8, nutrivet L 2.5, potassium metabisulfate 1.2,
vegetable oil 38, fish meal 170 and powdered milk 150.
The animals were fasted for 24 h before the experiment but
were given free access to tap water.
Plant material and extract preparation
A total of 1021 g of dried ginger rhizome was bought from a
wholesale market in Karachi, Pakistan. Ginger rhizomes
were sliced to expose the inner part, soaked in 8 L of 70%
aqueous/methanol and kept for a total of 3 days. After 3 days,
the extract was filtered through a porous cloth and the filtrate
collected while the plant material was again soaked in 8 L of
solvent for 3 days, twice. The combined filtrate was filtered
through Whatman qualitative grade-1 filter paper and later
concentrated in a rotary evaporator to obtain a thick brown
extract (Zo.Cr; 129 g) with a yield of 12.6% (w/w).
Preliminary phytochemical analysis
The crude extract (Zo.Cr) was screened for the presence of
different classes of compounds by thin-layer chromatography
using silica gel G (E. Merck) plates of 0.25-mm thickness
(Wagner et al 1984; Gilani et al 2006). The extract was
dissolved in chloroform and methanol (2:1), while the
development of plates was carried out with chloroform and
methanol (3:17 v/v). After development, the plates were
sprayed with the following solvents and reagents for
detection of the respective classes of compounds: water
(lipophilic compounds); sulfuric acid and heating at 105˚C
for 5 min (organic compounds); 0.5% anisaldehyde in
sulfuric acid, glacial acetic acid and methanol (5:10:85 v/v)
(terpenoids); 10% antimony trichloride in chloroform
(flavonoids/terpenoids); 1% diphenylboric acid 2-aminoethyl
ester in methanol followed by 5% polyethylene glycol 4000
in 96% ethanol (flavonoids); 0.5% ninhydrin in acetone
(amino acids/peptides and secondary amines); 5% ethanolic
sodium hydroxide (anthraquinones); 5% aqueous ferric
chloride (tannins/phenols); 20% aqueous sodium carbonate
followed by Folin-Ciocalteu reagent (phenols); 0.5%
aqueous fast blue B salt followed by 0.1 M aqueous sodium
hydroxide (phenols); Dragendorff reagent (alkaloids); and
dilute sodium hydroxide (coumarins). Reagents were
prepared according to Stahl (1969). Detection was carried
out visually in visible light and under UV light (l = 365 nm).
Saponins were detected by observing froth formation by the
extract in a test tube after regular shaking.
Isolated rat stomach fundus
Rats were killed by cervical dislocation (Ghayur & Gilani
2005a; Ghayur et al 2007). The stomach was removed and
placed in Kreb’s solution for isolating the fundus. The
stomach was opened along the lesser curvature and divided
into two longitudinal strips, 2 mm wide and 15 mm long.
Each strip preparation was mounted separately in a 10-mL
Pharmacological basis for use of ginger in dementia
tissue bath with Kreb’s solution at 37˚C and aerated with
carbogen (5% CO2 in O2). The composition of Kreb’s solution
was (mM): NaCl 118.2, NaHCO3 25.0, CaCl2 2.5, KCl 4.7,
KH2PO4 1.3, MgSO4 1.2 and glucose 11.7 (pH 7.4). Basal
tension of 1 g was applied to each tissue and the responses
recorded following an equilibrium period of 60 min. Submaximal concentrations of CCh (0.3 mM) were tested
repeatedly to stabilize the preparation and the responses
were recorded through isotonic Harvard transducers coupled
with Harvard student oscillographs.
Experimental protocol
The ginger crude extract and its pure compounds were tested
first on the resting baseline of fundic preparations. A possible
stimulant activity was compared with that of standard CCh
and serotonin. To determine the mode of action of this
stimulant effect, the test substance response was challenged
with antagonists such as hexamethonium (0.3 mM), atropine
(0.1 mM) and methysergide (0.1 mM). Later, the extract and
pure compounds were also tested for a possible relaxant
activity. To assess whether the spasmolytic activity of the
ginger extract and its pure compounds was mediated through
Ca++-channel blockade (CCB), high K+ (80 mM) was used to
depolarize the fundic preparations (Farre et al 1991) and
produce a sustained contraction. Samples were then added
in a cumulative fashion to obtain concentration-dependent
inhibitory responses (van-Rossum 1963). The relaxation of
tissue preparations precontracted with high K + was
expressed as a percentage of the control response mediated
by high K+. Contractions of smooth muscles induced by high
K+ (>30 mM) are known to be mediated via influx of Ca++
through voltage-operated Ca++ channels (VOCC) from
extracellular fluid. A substance that inhibits these contractions might possibly act through CCB (Bolton 1979).
To further investigate possible CCB activity of the extract,
the tissue preparation was allowed to stabilize in normal Kreb’s
solution, which was then replaced with Ca++-free Kreb’s
solution containing EDTA (0.1 mM) for 30 min in order to
remove all the Ca++ from the tissue to achieve a Ca++-free
environment. This solution was further replaced with K+-rich
and Ca++-free Kreb’s solution, having the following composition: KCl 50, NaCl 91.04, MgSO4 1.05, NaHCO3 11.90,
glucose 5.55 and EDTA 0.1 mM. Following an incubation
period of 30 min, contractions were induced with externally
administered Ca++. These externally administered Ca++ contractions were reproduced and when found superimposable
(usually after two cycles), the tissue was pretreated with
increasing concentrations of extract and positive control
(separately) for 60 min to test for a possible CCB effect. The
externally administered Ca++-induced contractions were reconstructed in the presence of different concentrations of Zo.Cr,
while verapamil, a standard CCB (Bolton 1979; Farre et al
1991), was used as a positive control.
To screen the extract for potential cholinesterase inhibitory activity in the fundus preparations, maximal peak
responses of ACh (1 mM) were reproduced. Later, these
control peak responses were pretreated for 30 min with
increasing concentrations of Zo.Cr or physostigmine,
1377
a standard cholinesterase inhibitor (Robinson 1968). Any
enhancement in the control response of ACh, after pretreatment
with extract or standard for 30 min, was possibly due to
inhibition of cholinesterase enzymes, which resulted in an
augmented ACh response (Gilani et al 2004, 2005). Further
confirmatory tests for cholinesterase inhibitory activity were
performed using an enzyme inhibition assay as detailed below.
Enzyme assay for cholinesterase inhibition
Acetylcholinesterase (AChE) and butyrylcholinesterase
(BuChE) inhibitory activities of Zo.Cr and pure compound
were measured in-vitro by a modified spectrophotometric
method developed by Ellman et al (1961). Electric eel AChE
(type VI-S; Sigma Chemical Company), and horse serum
BuChE (Sigma) were used as the enzyme source, while
acetylthiocholine (ATCh) iodide and butyrylthiocholine
(BTCh) chloride (Sigma) were used as substrates in the
respective enzyme assays. Ellman reagent (i.e. 5,5-dithiobis
(2-nitro)benzoic acid or DTNB; Sigma) was used to develop the
chromogenic marker for the measurement of the cholinesterase
activity. Sodium phosphate buffers (1 mM) at pH 7.0 and 8.0
were used to prepare the enzyme working solution and in the
assay mixture, respectively. Concentrated enzyme preparations
were prepared and stored at -70˚C, and diluted at the time of the
experiments (the activity of the enzyme was not affected under
these conditions for several months).
All the inhibition studies were performed in 96-well
microtitre plates. For the assay procedure, 140 mL of 0.1 mM
sodium phosphate buffer (pH 8.0), 20 mL of test compound
solution, and 20 mL of AChE/BuChE solution were mixed
and incubated for 15 min at 25˚C. Then, 10 mL of DTNB
was added and the reaction was then initiated with the
addition of 10 mL of ATCh/BTCh (0.71 and 0.2 mM of
ATCh and BTCh, respectively). The hydrolysis of ATCh and
BTCh was monitored by measuring the formation of the
yellow 5-thio-2-nitrobenzoate anion as a result of the
reaction of DTNB with thiocholine at a wavelength of
412 nm using a SpectraMax microplate spectrophotometer
(Molecular Devices, CA, USA). Test substances were
dissolved in 5% ethanol, while the control received only
the same volume of the solvent. All reactions were performed
in triplicate and the initial rate was measured as the rate of
change in optical density (OD) min-1 and used in subsequent
calculations. According to Ellman et al (1961), since the
extinction coefficient of the yellow anion is known, the rate
of the enzymatic reaction can be calculated based on the
following equation:
Rate (mol L-1 min-1) = change in absorbance min-1/13 600.
The percentage enzyme inhibition by the test sample was
calculated using the following formula:
% Inhibition = 100 - (change in absorbane of test/change in
absorbance of control ¥ 100)
The test reaction was the enzymatic reaction containing the
test sample, while the control was the enzymatic reaction
lacking the test sample. Physostigmine was used as a
standard cholinesterase inhibitor (Robinson 1968).
Muhammad N. Ghayur et al
Statistical analysis
All the data are expressed as mean ± s.e.m. (n is the number of
experiments) and the median effective concentrations (EC50
values) with 95% confidence intervals. The unpaired Student’s
t-test, one-way and two-way analysis of variance were used to
compare mean values, while for median values the Kruskal–
Wallis test was used (GraphPAD software; GraphPAD,
San Diego, CA, USA). A probability of less than 0.05 was
considered statistically significant. Concentration–response
curves were analysed by non-linear regression (GraphPAD
software).
A
100
% of CCh maximum response
1378
Results
80
60
40
20
0
Phytochemical analysis
Effect of extract on resting baseline of rat stomach fundus
Zo.Cr produced a concentration-dependent (0.03–5.00 mg mL-1)
contractile effect (Figure 1A) on the resting baseline of rat
stomach fundus, with an EC50 value of 0.26 mg mL-1
(0.17–0.40, n = 5). The efficacy of the spasmogenic effect was
86.8 ± 2.8% of the CCh maximum effect (Figure 1A). An extract
concentration of 5 mg mL-1 showed relaxation of the tissue.
Pretreatment of the tissue with atropine (0.1 mM), but not with
hexamethonium (0.3 mM) or methysergide (0.1 mM), completely
blocked the effect of Zo.Cr. The effect of CCh was also blocked
by atropine.
Spasmolytic effect of extract on rat stomach fundus
In the atropinized (0.1 mM) tissue preparation, Zo.Cr inhibited
high K+-induced contractions in a concentration-dependent
manner (0.3–3.0 mg mL-1) with an EC50 value of 0.81 mg mL-1
(0.73–0.89, n = 5; Figure 1B). In order to further investigate this
relaxant effect of the extract, contractions were induced with
externally administered Ca++ (in an initial Ca++-free environment)
and these Ca++ contractions were pretreated with increasing
concentrations of extract. Zo.Cr (0.1–0.3 mg mL-1, n = 4) shifted
these Ca++-induced contractions to the right (Figure 2A), similar
to the effect exhibited by verapamil (0.03–0.10 mM, n = 4;
Figure 2B).
Preliminary screening of the extract for a cholinesterase
inhibitory effect in rat stomach fundus
In the presence of increasing concentrations of the extract
(0.0001–0.0030 mg mL-1, n = 3–12), the stimulant effect of a
fixed dose of ACh (1 mM) was enhanced in a concentrationdependent fashion (Figure 3A). Similarly, physostigmine
(0.01–0.10 mM, n = 5–7) also potentiated the ACh peak response
(Figure 3B), indicating similarity in the modes of action.
0.01
0.1
1
Zo.Cr concn (mg mL–1)
10
0.01
0.1
1
Zo.Cr concn (mg mL–1)
10
B
100
80
% of K+ contraction
Zo.Cr showed the presence of lipophilic and organic
compounds along with the following classes of compounds:
terpenoids, flavonoids, amino acids/peptides, secondary
amines, phenols, alkaloids and saponins. Coumarins and
anthraquinones were absent in the extract.
60
40
20
0
Figure 1 Concentration–response curves showing the effect of dried
ginger crude extract (Zo.Cr) on resting baseline (A) and high K+ (80 mM)
contracted (B) isolated rat stomach fundus tissues. The spasmogenic
effect was calculated in comparison with the carbachol (CCh) maximum
response, while the spasmolytic effect was calculated in comparison with
the % of K+ contraction. Values shown are mean ± s.e.m., n = 5. There
was a significant difference between the individual extract concentrations in both the curves (P < 0.0001; one-way analysis of variance).
Effect of extract on in-vitro cholinesterase enzyme
inhibition assay
In the in-vitro assay, the extract was tested for a potential
inhibitory effect on both BuChE and AChE enzymes. It was
observed that Zo.Cr concentration-dependently (0.0625–
1.0000 mg mL-1, n = 3) inhibited BuChE, with an EC50
value of 0.18 mg mL-1 (0.17–0.19, n = 3). Maximum BuChE
enzyme inhibition produced by the extract was 71.9 ± 0.6% at
a concentration of 1 mg mL-1. Compared with the maximum
inhibition shown against BuChE, the extract (1 mg mL-1)
showed only minor inhibition of AChE (32.2 ± 1.7%;
P < 0.0001). Physostigmine, the standard cholinesterase
inhibitor, inhibited both BuChE and AChE, with EC50 values
1379
Pharmacological basis for use of ginger in dementia
A
A
Control (ACh 1M)
80
125
60
40
20
**
Control + Zo.Cr
Zo.Cr 0.3 mg mL–1
**
**
0.001
150
0.0003
Control
Zo.Cr 0.1 mg mL–1
% of control response
% of control maximum response
100
**
100
75
50
25
0
–3.0
–2.5
–2.0
0
–1.5
0
Log Ca++ concn (M)
B
100
Zo.Cr concn (mg mL–1)
Control
B
Control (ACh 1M)
150
Control + physostigmine
**
60
125
% of control response
% of control maximum response
Verapamil 0.03 M
Verapamil 0.1 M
80
0.003
–3.5
0.0001
–4.0
40
20
0
–4.0
–3.5
–3.0
–2.5
–2.0
–1.5
*
100
75
50
25
Log Ca++ concn (M)
of 0.85 mM (0.83–0.89, n = 4) and 0.04 mM (0.03–0.06, n = 4),
respectively.
Effect of ginger pure compounds on rat stomach
fundus and cholinesterase assay
When tested on the resting baseline of rat stomach fundus,
the ginger pure compounds, namely 6-gingerol, 8-gingerol,
0.1
0.03
0.01
0
0
Figure 2 Concentration–response curves showing the effect of increasing
concentrations of dried ginger crude extract (Zo.Cr) (A) and verapamil (B),
on Ca++ concentration–response curves constructed in a Ca++-free medium in
isolated rat stomach fundus. Values shown are mean ± s.e.m., n = 4. There
was a significant difference between Zo.Cr and verapamil treatments
compared with control curves (P < 0.0001) and between individual
concentrations in all curves (P < 0.0001; two-way analysis of variance).
Physostigmine concn (M)
Figure 3 Bar diagrams showing the effect of increasing concentrations
of dried ginger crude extract (Zo.Cr) (A) and physostigmine (B) on
control acetylcholine (ACh, 1 mM) responses in rat stomach fundus
tissues. Values shown are mean ± s.e.m. n = 3–12. *P < 0.05 and
**P < 0.01 compared with the ACh control response (one-way analysis
of variance followed by Dunnett’s test).
10-gingerol and 6-shogaol (Figure 4), showed no effect up to
the tested concentration of 1 mM. Anticipating some relaxant
activity, the compounds were then administered against high
K+-induced contractions. All of the compounds (6-gingerol,
1380
Muhammad N. Ghayur et al
O
O
100
O
O
6-Gingerol
O
O
% of K+ contraction
80
60
40
6-Gingerol
20
O
6-Shogaol
8-Gingerol
O
8-Gingerol
O
O
10-Gingerol
0
10
100
1000
Concn (M)
O
O
10-Gingerol
O
Figure 5 Concentration–response curves showing the relaxant effect
of increasing concentrations of ginger compounds, 6-, 8- and 10-gingerol
and 6-shogaol, on high K+ (80 mM) induced contractions in isolated rat
stomach fundic preparations. Values shown are mean ± s.e.m., n = 3.
There was a significant difference between all the curves (P < 0.0001)
and between individual concentrations in all the curves (P < 0.0001;
two-way analysis of variance).
Discussion
HO
O
6-Shogaol
Figure 4 Chemical structures of the standard ginger compounds
6-, 8- and 10-gingerol and 6-shogaol.
8-gingerol, 10-gingerol and 6-shogaol) showed concentration-dependent (30–1000 mM) relaxant activity (Figure 5),
with EC50 values of 62.2 mM (52.9–73.1, n = 3), 164.2 mM
(142.0–189.9, n = 3), 528.4 mM (112.6–2480.0, n = 3) and
91.1 mM (80.6–103.1, n = 3), respectively. Although the
EC50 values do not indicate any difference (P > 0.05),
Figure 5 shows that the compound 6-gingerol was significantly more potent in mediating the relaxant effect than the
other compounds.
Owing to insufficient quantity of pure compounds, we
could only screen the most potent compound, 6-gingerol, for
in-vitro cholinesterase inhibitory activity. The compound
was tested against the cholinesterase enzymes, AChE and
BuChE. It was observed that the compound was inactive
against AChE when tested up to a concentration of 1 mM.
For BuChE, 6-gingerol showed a concentration-dependent
(0.5–1.0 mM) inhibitory effect, with an EC50 value of
0.89 mM (0.76–1.03, n = 3). The maximum inhibitory effect
produced by the compound for BuChE was 54.0 ± 1.5% with
concentration of 1 mM.
This study was performed to rationalize and investigate the
use of dried ginger in dementia (Kapoor 1990; Duke 1995;
Khan 2005). The aqueous/methanolic extract of dried ginger
showed a concentration-dependent contractile effect on the
resting baseline of rat stomach fundus tissue preparations. This
stimulant activity was resistant to blockade by methysergide,
a non-selective serotonin antagonist (van Zwieten et al 1990)
and hexamethonium, a ganglion blocker (Klowden et al 1978).
Rat stomach fundus is known to have serotonin receptors that
mediate contractility (Komada & Yano 2007). The stimulant
effect of Zo.Cr was completely abolished in the presence of
atropine, a muscarinic receptor blocker (Arunlakhshana &
Schild 1959). Atropine is known to block the effect (not
receptors) of nicotine, as the end effect of nicotine in
gastrointestinal tract is ultimately due to release of ACh,
which as a result acts on muscarinic receptors (Brown &
Taylor 1995). The observation that the stimulant effect of
Zo.Cr was insensitive to hexamethonium but sensitive to
atropine indicates that the spasmogenic effect was mediated
through stimulation of muscarinic receptors. The presence of
muscarinic receptors has been reported in rat stomach fundus
(Ghayur et al 2007) mediating contractile responses, with the
muscarinic M1 and M3 subtypes being most important
(Milovanović & Janković 1997; Smaili et al 1997).
In addition to the ACh-like spasmogenic effect, Zo.Cr
also exhibited a spasmolytic effect in fundus. The extract,
for its spasmolytic effect, not only relaxed the high K+
Pharmacological basis for use of ginger in dementia
(80 mM)-induced contractions in the tissues, but also inhibited
contractions that were induced, in initial Ca++-free conditions,
with externally administered Ca++. This activity is a
typical characteristic of Ca++ antagonists (Furchgott 1961).
Verapamil, a standard CCB (Bolton 1979; Farre et al 1991),
also exhibited similar results. Although the results suggest
interaction of the extract with VOCC, this cannot be
confirmed until more intensive studies are performed on Ca++
currents at the level of single smooth muscle cells. If the
possible presence of Ca++ antagonistic activity is confirmed in
the extract, then this would be of special interest as CCBs have
been found to be useful in preventing dementia and AD. This is
mainly due to the role played by Ca++ in regulating brain
functions (Vagnucci & Li 2003). Ca++ links membrane
excitation to subsequent intracellular enzymatic response and
the change in Ca++ homeostasis is linked to ageing, with
consequences on higher cortical functions (Arrieta & Birks
2001). Cytosolic [Ca++]i also increases with ageing, mediated
via neuronal cell body VOCC. This activates an apoptotic
gene that results in cholinergic neuronal death (Branconnier
et al 1992). CCBs can thus have a palliative effect on
progression and prevention of AD.
Preliminary screening of the extract for a possible
cholinesterase inhibitory effect was done in rat stomach
fundus. Fixed concentrations of ACh (1 mM) were pretreated
with increasing concentrations of Zo.Cr. The extract
potentiated ACh peak responses, similar to physostigmine,
a standard cholinesterase inhibitor (Robinson 1968), thus
indicating similarity in the modes of action. The cholinesterase inhibitory effect of Zo.Cr was confirmed in the in-vitro
cholinesterase assay when, similar to physostigmine, it
inhibited both BuChE and AChE enzymes. Interestingly,
the extract was significantly more potent in inhibiting BuChE
than AChE enzymes (P < 0.0001). Cholinesterase enzymes
bind and cleave ACh to choline and acetate. Inhibitors of
cholinesterase produce a cholinergic action by preventing
hydrolysis of ACh formed endogenously at the cholinergic
nerve endings (Mycek et al 1997) and are considered useful
in AD (Palmer 2002). This BuChE-specific inhibitory effect
of the extract is of particular interest given the recent interest
in AD therapy focusing on the benefits of specific BuChE
inhibitors (e.g. cymserine and MF-8622) and dual BuChE/
AChE inhibitors (e.g. rivastigmine) over the well known
specific AChE inhibitors (e.g. donepezil and galantamine)
(Greig et al 2002; Mesulam et al 2002; Rösler 2002). In
healthy brains, AChE is known to be the main player (80%
workload), compared with BuChE, when it comes to
hydrolysis of ACh (Greig et al 2001). Recent research has
shown that in patients with severe AD, BuChE activity
increases, while that of AChE either stays stable or declines
(by as much as 90%), indicating the importance of targeting
BuChE in severely diseased AD patients (Giacobini 2003;
Greig et al 2001).
In order to trace some of the activities seen with the
extract, we acquired some commercially available known
phenolic compounds of ginger (Gilani & Ghayur 2005a, b;
Langner et al 1998). Three different gingerols (6-, 8- and
10-gingerol) and one shogaol (6-shogaol) were tested on
isolated fundus. For reference, we performed a chemical
1381
analysis of the extract and found that the extract did contain
phenolic compounds. Unlike Zo.Cr, none of the tested
compounds showed any spasmogenic activity, but all
exhibited a spasmolytic effect on high K+-contracted rat
fundus, thus indicating activity via blockade of VOCC.
6-Gingerol was the most potent compared with the other
compounds (P < 0.0001). Gingerols and shogaols are the
main components of ginger. If these compounds do not
possess the ACh-like spasmogenic activity it might be due to
the many other compounds present in ginger as shown by the
chemical analysis. Among the gingerols, the spasmolytic
activity decreased with increasing size of the side chain in
the chemical structure (Figure 4). Both 6-gingerol and
6-shogaol have the same number of C atoms in their side
chains, however the former, which lacks an extra hydroxyl
group and a double bond in the side chain, was more potent
than the latter. Due to experimental limitations, we cannot
stipulate the concentrations of these pure compounds in the
extract. However, in a recent study, Lee et al (2007) did a
very similar quantification. They reported that these same
gingerols (6-, 8- and 10-gingerol) and 6-shogaol have a
concentration of around 2–9 mg g-1 of the raw dried herb,
while the amounts were 5-times lower in the dried herb
extract.
Owing to the limited quantity of the compounds, we could
only test 6-gingerol for anticholinesterase activity in the
in-vitro assay. Similar to the extract, 6-gingerol also showed a
BuChE-specific inhibitory effect, with no activity against
AChE. Thus, we have identified a possible specific BuChEinhibiting compound, with CCB potential, from a natural
source. We have in the past identified a number of pure
compounds with dual cholinesterase and CCB activities
(Khalid et al 2004; Choudhary et al 2005a, b; Atta-ur-Rahman
et al 2006). Related to our findings, there have been recent
advances in the development of hybrid molecules/designer
compounds with the ability to target multiple sites of actions
in the treatment of AD. This may include cholinesterase
inhibitory activity along with some particular receptor
blocking activity, antioxidant activity or even CCB activity
(Decker 2007).
The concentrations at which the extract exhibited the
muscarinic, possible Ca++ antagonistic and cholinesterase
inhibitory activities are comparable with the concentrations
of other extracts reported in the literature. We did not
perform any in-vivo tests; however, comparing the results
seen here with some previously published results (from
studies with in-vivo data) of fresh ginger extract (Ghayur &
Gilani 2005a, 2006), we can say that dried ginger extract
mediates its effects at concentrations that correlate with the
1–2 g of raw dried ginger that is usually taken by people to
get the required relief.
In the past, different studies have shown that ginger
possesses anxiolytic properties (Hasenöhrl et al 1996),
improves inhibitory avoidance learning (Topic et al 2002a),
facilitates spatial learning along with reducing oxidative
stress (Topic et al 2002b) and inhibits -amyloid peptideinduced cytokine and chemokine expression in monocytes,
thus delaying the onset and progression of neurodegenerative
disorders (Grzanna et al 2004). All the studies mentioned
1382
Muhammad N. Ghayur et al
above, together with our findings, suggest a possible benefit
of ginger in memory disorders such as AD.
Conclusion
The results show that dried ginger extract possesses muscarinic,
Ca++ antagonist and specific BuChE inhibitory properties. The
gingerols and 6-shogaol all showed spasmolytic activities
possibly mediated via Ca++ antagonism, while 6-gingerol also
exhibited BuChE-specific inhibitory activity in the in-vitro
cholinesterase inhibition assay. These results give support to the
traditional use of ginger in dementia. The results of this study
are only preliminary and further studies are necessary to
determine the mechanism of action of this herb at the receptor
(muscarinic), channel (Ca++), enzyme (cholinesterase) and
signal pathway levels. Ultimately, only clinical studies can
determine the overall safety and efficacy of the ginger extract,
including its ability to cross the blood–brain barrier (as only
then can it be of any use in memory disorders).
References
Arrieta, L., Birks, J. (2001) Nimodipine for primary degenerative,
mixed and vascular dementia. Cochrane Database Syst. Rev.
1: CD000147
Arunlakhshana, O., Schild, H. O. (1959) Some quantitative uses of
drug antagonists. Br. J. Pharmacol. 14: 48–58
Atta-ur-Rahman, Khalid, A., Sultana, N., Ghayur, M. N., Mesaik, M. A.,
Khan, M. R., Gilani, A. H., Choudhary, M. I. (2006) New natural
cholinesterase inhibiting and calcium channels blocking quinoline
alkaloids. J. Enzyme Inhib. Med. Chem. 21: 703–710
Bolton, T. B. (1979) Mechanism of action of transmitters and other
substances on smooth muscles. Physiol. Rev. 59: 606–718
Branconnier, R. J., Branconnier, M. E., Walshe, T. M., McCarthy, C.,
Morse, P. A. (1992) Blocking the Ca(2+)-activated cytotoxic
mechanisms of cholinergic neuronal death: a novel treatment strategy
for Alzheimer’s disease. Psychopharmacol. Bull. 28: 175–181
Brown, J. H., Taylor, P. (1995) Muscarinic receptor agonists and
antagonists. In: Hardman, J. G., Limbird, L. E. (eds) Goodman
and Gilman’s the pharmacological basis of therapeutics.
McGraw-Hill, New York, pp 141–160
Choudhary, M. I., Nawaz, S. A., Zaheer-ul-Haq, Lodhi, M. A.,
Ghayur, M. N., Jalil, S., Riaz, N., Yousuf, S., Malik, A., Gilani, A. H.,
Atta-ur-Rahman (2005a) Withanolides, a new class of natural
cholinesterase inhibitors with calcium antagonistic properties.
Biochem. Biophys. Res. Commun. 334: 276–287
Choudhary, M. I., Nawaz, S. A., Zaheer-ul-Haq, Azim, M. K.,
Ghayur, M. N., Lodhi, M. A., Jalil, S., Khalid, A., Ahmed, A.,
Rode, B. M., Atta-ur-Rahman, Gilani, A. H., Ahmad, V. U.
(2005b) Juliflorine: a potent natural peripheral anionic-sitebinding inhibitor of acetylcholinesterase with calcium-channel
blocking potential, a leading candidate for Alzheimer’s disease
therapy. Biochem. Biophys. Res. Commun. 332: 1171–1179
Decker, M. (2007) Recent advances in the development of hybrid
molecules/designed multiple compounds with antiamnesic properties. Mini Rev. Med. Chem. 7: 221–229
Duke, J. (1995) Dr. Duke’s phytochemical and ethnobotanical
databases. http://www.ars-grin.gov/duke/ (accessed 17 March 2008)
Ellman, G. L., Courtney, K. D., Andres, V., Feather-Stone, R. M.
(1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7: 88–95
Farre, A. J., Columbo, M., Fort, M., Gutierrez, B. (1991)
Differential effects of various Ca++ antagonists. Gen. Pharmacol.
22: 177–181
Foster, S. (2000) Ginger, your food is your medicine. http://
stevenfoster.com/education/monograph/ginger.html (accessed 17
March 2008)
Furchgott, R. F. (1961) Spiral-cut strip of rat aorta for in vitro
studies of responses of arterial smooth muscle. Methods Med.
Res. 8: 177–186
Ghayur, M. N., Gilani, A. H. (2005a) Pharmacological basis for the
medicinal use of ginger in gastrointestinal disorders. Dig. Dis.
Sci. 50: 1889–1897
Ghayur, M. N., Gilani, A. H. (2005b) Ginger lowers blood pressure
through blockade of voltage-dependent calcium channels.
J. Cardiovasc. Pharmacol. 45: 74–80
Ghayur, M. N., Gilani, A. H. (2006) Species differences in the
prokinetic effects of ginger. Int. J. Food Sci. Nutr. 57: 65–73
Ghayur, M. N., Gilani, A. H. (2007) Inhibitory activity of ginger
rhizome on airway and uterine smooth muscle preparations. Eur.
Food Res. Technol. 224: 477–481
Ghayur, M. N., Gilani, A. H., Afridi, M. B., Houghton, P. J. (2005)
Cardiovascular effects of ginger aqueous extract and its phenolic
constituents are mediated through multiple pathways. Vasc.
Pharmacol. 43: 234–241
Ghayur, M. N., Khan, A. H., Gilani, A. H. (2007) Ginger facilitates
cholinergic activity possibly due to blockade of muscarinic
autoreceptors in rat stomach fundus. Pak. J. Pharm. Sci. 20:
231–235
Ghayur, M. N., Gilani, A. H., Janssen, L. J. (2008) Ginger attenuates
acetylcholine-induced contraction and Ca2+ signaling in murine
airway smooth muscle cells. Can. J. Physiol. Pharmacol. 86: 264–271
Giacobini, E. (2003) Cholinergic function and Alzheimer’s disease.
Int. J. Geriatr. Psychiatry 18 (Suppl. 1): S1–S5
Gilani, A. H., Ghayur, M. N. (2005) Ginger: from myths to reality.
In: Gottschalk-Batschkus, C. E., Green, J. C. (eds) Ethnotherapies
in the cycle of life. BOD - Books on Demand/Ethnomed Institut
für Ethnomedizin e.V., Munich, pp 307–315
Gilani, A. H., Ghayur, M. N., Saify, Z. S., Ahmed, S. P., Choudhary,
M. I., Khalid, A. (2004) The presence of cholinomimetic and
acetylcholinesterase inhibitory constituents in betel nut. Life Sci.
75: 2377–2389
Gilani, A. H., Ghayur, M. N., Khalid, A., Haq, Z., Choudhary, M. I.,
Rahman, A. (2005) The presence of antispasmodic, antidiarrhoeal, antisecretory and acetylcholinesterase inhibitory constituents in Sarcococca saligna. Planta Med. 71: 120–125
Gilani, A. H., Ghayur, M. N., Houghton, P. J., Jabeen, Q.,
Kazim, S. F., Jumani, M. I., Saeed, S. A. (2006) Studies on the
hypotensive, cardio-suppressant, vasodilator and antiplatelet
activities of betel nut crude extract and its constituents. Int. J.
Pharmacol. 2: 33–41
Greig, N. H., Utsuki, T., Yu, Q., Zhu, X., Holloway, H. W., Perry, T.,
Lee, B., Ingram, D. K., Lahiri, D. K. (2001) A new therapeutic
target in Alzheimer’s disease treatment: attention to butyrylcholinesterase. Curr. Med. Res. Opin. 17: 159–165
Greig, N. H., Lahiri, D. K., Sambamurti, K. (2002) Butyrylcholinesterase: an important new target in Alzheimer’s disease therapy.
Int. Psychogeriatr. 14 (Suppl. 1): 77–91
Grzanna, R., Phan, P., Polotsky, A., Lindmark, L., Frondoza, C. G.
(2004) Ginger extract inhibits beta-amyloid peptide-induced
cytokine and chemokine expression in cultured THP-1 monocytes. J. Altern. Complement. Med. 10: 1009–1013
Hasenöhrl, R. U., Nichau, C. H., Frisch, C. H., De Souza Silva, M. A.,
Huston, J. P., Mattern, C. M., Häcker, R. (1996) Anxiolytic-like
effect of combined extracts of Zingiber officinale and Ginkgo biloba
in the elevated plus-maze. Pharmacol. Biochem. Behav. 53: 271–275
Pharmacological basis for use of ginger in dementia
Howes, M. J., Houghton, P. J. (2003) Plants used in Chinese and
Indian traditional medicine for improvement of memory and
cognitive function. Pharmacol. Biochem. Behav. 75: 513–527
Iqbal, Z., Lateef, M., Akhtar, M. S., Ghayur, M. N., Gilani, A. H.
(2006) In vivo anthelmintic activity of ginger against gastrointestinal nematodes of sheep. J. Ethnopharmacol. 106: 285–287
Kapoor, L. D. (1990) Handbook of Ayurvedic medicinal plants.
CRC Press, Boca Raton
Khalid, A., Haq, Z., Ghayur, M. N., Feroz, F., Rahman, A., Gilani, A. H.,
Choudhary, M. I. (2004) Cholinesterase inhibitory and spasmolytic
potential of steroidal alkaloids. J. Steroid Biochem. Mol. Biol. 92:
477–484
Khan, M. S. (2005) Ginger. http://www.geocities.com/mutmainaa/
food/ginger.html (accessed 17 March 2008)
Klowden, A. J., Ivankovich, A. D., Miletich, D. J. (1978) Ganglionic
blocking drugs: general considerations and metabolism. Int.
Anesthesiol. Clin. 16: 113–150
Komada, T., Yano, S. (2007) Pharmacological characterization of
5-hydroxytryptamine-receptor subtypes in circular muscle from
the rat stomach. Biol. Pharm. Bull. 30: 508–513
Langmead, C. J., Watson, J., Reavill, C. (2008) Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 117: 232–243
Langner, E., Greifenberg, S., Gruenwald, J. (1998) Ginger: history
and use. Adv. Ther. 15: 25–44
Lee, S., Khoo, C., Halstead, C. W., Huynh, T., Bensoussan, A.
(2007) Liquid chromatographic determination of 6-, 8-,
10-gingerol, and 6-shogaol in ginger (Zingiber officinale) as the
raw herb and dried aqueous extract. J. AOAC Int. 90: 1219–1226
Mesulam, M., Guillozet, A., Shaw, P., Quinn, B. (2002) Widely
spread butyrylcholinesterase can hydrolyze acetylcholine in the
normal and Alzheimer brain. Neurobiol. Dis. 9: 88–93
Milovanović, D. R., Janković, S. M. (1997) Pharmacologic characterization of muscarine receptor subtypes in rat gastric fundus
mediating contractile responses. Indian J. Med. Res. 105: 239–245
Muir, J. L. (1997) Acetylcholine, aging, and Alzheimer’s disease.
Pharmacol. Biochem. Behav. 56: 687–696
1383
Mycek, M. J., Harvey, R. A., Champe, P. C. (1997) Drugs affecting
the autonomic nervous system. In: Harvey, R. A., Champe, P. C.
(eds) Lippincott’s illustrated reviews; pharmacology. LippincottRaven, New York, pp 27–29
Palmer, A. M. (2002) Pharmacotherapy for Alzheimer’s disease:
progress and prospects. Trends Pharmacol. Sci. 23: 426–433
Robinson, B. (1968) The alkaloids. Academic Press, New York
Rösler, M. (2002) The efficacy of cholinesterase inhibitors in
treating the behavioural symptoms of dementia. Int. J. Clin.
Pract. 127 (Suppl.): 20–36
Smaili, S. S., Oshiro, M. E., Ferreira, A. T., Jurkiewicz, A. (1997)
M3 receptor mobilizes intracellular calcium in rat stomach
fundus. Ann. NY Acad. Sci. 812: 200–202
Stahl, E. (1969) Thin layer chromatography. Springer-Verlag,
Berlin
Topic, B., Hasenöhrl, R. U., Häcker, R., Huston, J. P. (2002a)
Enhanced conditioned inhibitory avoidance by a combined
extract of Zingiber officinale and Ginkgo biloba. Phytother.
Res. 16: 312–315
Topic, B., Tani, E., Tsiakitzis, K., Kourounakis, P. N., Dere, E.,
Hasenöhrl, R. U., Häcker, R., Mattern, C. M., Huston, J. P.
(2002b) Enhanced maze performance and reduced oxidative
stress by combined extracts of Zingiber officinale and Ginkgo
biloba in the aged rat. Neurobiol. Aging 23: 135–143
Vagnucci, A. H., Li, W. W. (2003) Alzheimer’s disease and
angiogenesis. Lancet 361: 605–608
van-Rossum, J. M. (1963) Commulative dose-response curves. II.
Techniques for the making of dose-response curves in isolated
organs and the evaluation of drug parameters. Arch. Int.
Pharmacodyn. Ther. 143: 199–230
van Zwieten, P. A., Blauw, G. J., van Brummelen, P. (1990)
Pathophysiological and pharmacotherapeutic aspects of serotonin and serotonergic drugs. Clin. Physiol. Biochem. 8 (Suppl. 3):
1–18
Wagner, H., Bladt, S., Zgainski, E. M. (1984) Plant drug analysis.
Springer-Verlag, Berlin